Pharmacokinetics, Efficacy and Tolerability of BIA 2-093
NCT02170064
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy
Interventions
DRUG:
BIA 2-093 (Eslicarbazepine acetate)
Sponsor
Bial - Portela C S.A.